Sep 14, 2020 / 08:30PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hello, everyone. Thanks for joining us today on the first day of our healthcare conference. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here. I'm delighted to have Invitae join us today and representing the company, we have Sean George, CEO; and Shelly Guyer, CFO. Both of you, welcome to the conference.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystSo to kick things off, Sean, just given the number of acquisitions you've done over the last couple of years, that was started with singular Jungla for your genetics and then YouScript, Genelex deployed, and now you have ArcherDX on the horizon as well. Can you walk us through Invitae's portfolio transformation and how it's brought you closer to your ultimate goal of a genome management business model and sort of really democratizing genetic sequencing for everybody really?
Sean Emerson George - Invitae Corporation - Co-Founder,